Lates News

According to a report released by China Galaxy on November 2, it gave a "recommended" rating to Kelun Pharmaceutical (002422.SZ). The reasons for the rating include: 1) The volume and price of large infusion and antibiotic intermediates are under pressure, and innovation has slightly increased R&D expenses; 2) The data on Lushenashu's monoclonal antibody were impressive at ESMO, and approval for second-line lung cancer has opened up market space. (Daily Economic News)